Patients
The Precision Cancer Medicine Registration Study of Omics Data from Genomic Information Analysis Leading to New Effective Therapy with FoundationOne CDx (PROFILE-F) was a prospective observational study conducted to characterize genomic aberrations and their clinical utility using genomic profiling. Thirteen pediatric and AYA cases with advanced solid tumors at our hospital who progressed or became resistant to standard systemic therapy were enrolled in this study. These patients underwent CGP between November 2017 and December 2019 under the PROFILE-F study. The PROFILE-F study was approved by the institutional review board of Tokyo Medical and Dental University (TMDU) (approval #G2018-002).